NCT01574274 - SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

July 31, 2021

Study Completion Date

July 1, 2027

Conditions

Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma

Interventions

DRUG

SC-PEG

11 doses Intravenously over one hour

DRUG

Oncaspar

16 doses Intravenously over one hour

Trial Locations (8)

Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian, New York

Montefiore Medical Center, New York

Children's Hospital Boston, Boston

Dana-Farber Cancer Institute, Boston

Hasbro Children's Hospital, Providence

McMaster University, Hamilton

Hospital Sainte Justine, University of Montreal, Montreal

Centre Hospitalier U. de Quebec, Québec